Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.

Abstract

The antitumor activity of a high molecular weight pro-drug of mitomycin C(MMC), MMC-dextran conjugate (MMC-D), was examined against various murine tumors under different experimental conditions. A single intraperitoneal injection of MMC-D exhibited higher antitumor activity against intraperitoneally inoculated B16 melanoma, Ehrlich ascites carcinoma, and P388 leukemia than MMC, but lower activity against BDF1 mouse-transplanted L1210 leukemia. Intratumoral injection of MMC-D showed a superior effect on subcutaneously implanted B16 melanoma, while intravenous injection of MMC-D exhibited reduced activity against P388 and L1210 leukemia compared with MMC. Prior administration of MMC-D at 24 hr before tumor inoculation resulted in a significant increase of the life span of mice bearing L1210 leukemia, suggesting that it shows sustained pharmacological activity. These differences between the activities of MMC-D and MMC in various tumor systems are considered to reflect the improved biopharmaceutical properties of MMC-D resulting from the modification of MMC into a polymeric drug.

• Authors: M Hashida, A Kato, T Kojima, S Muranishi, H Sezaki, N Tanigawa, K Satomura, Y Hikasa
• Journal: Gan (Gan) Vol. 72 Issue 2 Pg. 226-34 (Apr 1981) ISSN: 0016-450X [Print] Japan
• PMID: 6169584 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Dextrans
• Mitomycins
• Mitomycin

Topics

• Animals
• Antineoplastic Agents (administration & dosage, pharmacology, toxicity)
• Carcinoma, Ehrlich Tumor (drug therapy)
• Dextrans (administration & dosage, pharmacology, toxicity)
• Female
• Injections, Intravenous
• Leukemia L1210 (drug therapy)
• Male
• Melanoma (drug therapy)
• Mice
• Mice, Inbred Strains
• Mitomycin
• Mitomycins (administration & dosage, pharmacology, toxicity)
• Molecular Weight
• Neoplasms, Experimental (drug therapy)